Short Interest in Achilles Therapeutics plc (NASDAQ:ACHL) Expands By 35.4%

Achilles Therapeutics plc (NASDAQ:ACHL) was the recipient of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 215,700 shares, a growth of 35.4% from the October 31st total of 159,300 shares. Based on an average daily trading volume, of 670,800 shares, the short-interest ratio is presently 0.3 days. Currently, 0.6% of the shares of the stock are short sold.

Achilles Therapeutics Stock Performance

Achilles Therapeutics stock opened at $1.08 on Friday. Achilles Therapeutics has a 1-year low of $0.63 and a 1-year high of $1.76. The firm has a 50-day moving average of $1.02 and a 200-day moving average of $0.89. The firm has a market cap of $44.18 million, a P/E ratio of -0.65 and a beta of 1.35.

Institutional Trading of Achilles Therapeutics

A hedge fund recently raised its stake in Achilles Therapeutics stock. XTX Topco Ltd raised its position in shares of Achilles Therapeutics plc (NASDAQ:ACHL) by 239.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51,660 shares of the company’s stock after purchasing an additional 36,441 shares during the quarter. XTX Topco Ltd owned 0.13% of Achilles Therapeutics worth $42,000 as of its most recent SEC filing. 56.38% of the stock is owned by institutional investors.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.